| Xuchang Chenhe Bio-pharmaceutical Tech. Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (374) 579-3128 +86 15836530076 | |||
![]() |
wxh5168@126.com wxh5168@163.com | |||
![]() |
QQ chat | |||
| Chemical manufacturer since 2012 | ||||
| chemBlink standard supplier since 2013 | ||||
| Taizhou Tongxin Biopharmaceutical Technology Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 18652728585 | |||
![]() |
sales@allyrise.com | |||
![]() |
QQ chat | |||
| Chemical manufacturer since 2013 | ||||
| chemBlink standard supplier since 2013 | ||||
| Shanghai Rochi Pharmaceutical Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (21) 3875-1876 +86 15000076078 | |||
![]() |
info@rochipharma.com | |||
![]() |
QQ chat | |||
| Chemical manufacturer since 2009 | ||||
| chemBlink standard supplier since 2015 | ||||
| Hangzhou Cherry Pharmaceutical Technology Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (571) 8163-6070 +86 18042403330 | |||
![]() |
info@cherrypharmatech.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
| Chemical manufacturer since 2015 | ||||
| chemBlink standard supplier since 2015 | ||||
| Coresyn Pharmatech Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (571) 8662-6709 | |||
![]() |
sales@coresyn.com | |||
| Chemical manufacturer | ||||
| chemBlink standard supplier since 2016 | ||||
| Cangzhou Enke Pharma-tech Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (317) 510-5699 510-6597 +86 15533709196 | |||
![]() |
sale@enkepharma.com enkepharma@126.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
![]() |
WeChat: ymzhao | |||
| Chemical manufacturer since 2011 | ||||
| chemBlink standard supplier since 2016 | ||||
| Hangzhou Cyanochem Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 (571) 8522-0831 +86 17788583750 | |||
![]() |
info@cyanochem.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
| Chemical manufacturer since 2017 | ||||
| chemBlink standard supplier since 2018 | ||||
| Sichuan Taienkang Pharmaceutical Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
![]() |
+86 15102825326 | |||
![]() |
sales@taienkangpharma.com | |||
![]() |
Skype Chat | |||
![]() |
QQ chat | |||
| Chemical manufacturer since 2020 | ||||
| chemBlink standard supplier since 2024 | ||||
| Classification | Chemical reagent >> Organic reagent >> Ester |
|---|---|
| Name | 2-Methoxy-5-[[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]benzoic acid methyl ester |
| Synonyms | methyl 2-methoxy-5-[[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]benzoate |
| Molecular Structure | ![]() |
| Molecular Formula | C21H23N3O3 |
| Molecular Weight | 365.43 |
| CAS Registry Number | 1391712-57-4 |
| SMILES | C[C@@H](C1=NC=C(N1)C2=CC=CC=C2)NCC3=CC(=C(C=C3)OC)C(=O)OC |
| Solubility | Very slightly soluble (0.48 g/L) (25 ºC), Calc.* |
|---|---|
| Density | 1.187±0.06 g/cm3 (20 ºC 760 Torr), Calc.* |
| Index of Refraction | 1.592, Calc.* |
| Boiling Point | 600.0±55.0 ºC (760 mmHg), Calc.* |
| Flash Point | 316.7±31.5 ºC, Calc.* |
| * | Calculated using Advanced Chemistry Development (ACD/Labs) Software. |
| Hazard Symbols |
|
|---|---|
| Hazard Statements | H302-H315-H319-H335 Details |
| Precautionary Statements | P261-P280-P301+P312-P302+P352-P305+P351+P338 Details |
| SDS | Available |
|
2-Methoxy-5-[[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]benzoic acid methyl ester is a complex organic compound with potential applications in pharmaceutical and medicinal chemistry. This chemical substance is classified as a bioactive molecule with a unique structure, which includes a methoxy group, a benzoic acid ester, and a substituted imidazole group. The presence of these structural components suggests that this compound could have significant interactions with biological targets, making it of interest in the development of new therapeutics. The discovery of 2-Methoxy-5-[[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]benzoic acid methyl ester was driven by the need for novel molecules with the ability to modulate key biological pathways, particularly in the treatment of diseases related to inflammation or cancer. The imidazole moiety is known for its ability to interact with enzymes and receptors involved in these conditions, and the addition of the ethylamino group enhances the molecule's potential for specific binding to biological targets. The methoxy and benzoic acid ester groups contribute to the compound's stability and solubility, which are essential for its activity as a drug candidate. In laboratory studies, 2-Methoxy-5-[[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]benzoic acid methyl ester has shown promise in preclinical models of various diseases, including cancer and inflammatory disorders. Its ability to interact with specific receptors and enzymes may allow it to modulate critical pathways that influence cell growth, survival, and immune response. Research into the compound's mechanism of action suggests that it could inhibit certain protein-protein interactions that are central to the development and progression of disease. This makes it a candidate for further development as a targeted therapy in the treatment of conditions that involve abnormal cellular activity. One of the most intriguing aspects of 2-Methoxy-5-[[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]benzoic acid methyl ester is its potential to overcome the limitations of existing treatments for inflammatory diseases and cancers. By targeting specific molecular pathways, this compound could provide a more effective approach with fewer side effects compared to conventional therapies. In particular, its ability to selectively modulate protein interactions may lead to a new class of drugs that are both highly potent and precise in their action, reducing the risk of off-target effects. Although still in the early stages of development, 2-Methoxy-5-[[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]benzoic acid methyl ester represents a promising direction for the development of novel therapeutics. Its complex structure and bioactivity indicate that it has the potential to address important unmet medical needs in the treatment of cancer and inflammation. Further research and clinical trials will be necessary to determine its efficacy and safety in human patients, but its initial promise suggests it could play an important role in future therapeutic strategies. References 2016. Eluxadoline. Pharmaceutical Substances. URL: https://pharmaceutical-substances.thieme.com/ps/search-results?docUri=KD-05-0130 |
| Market Analysis Reports |
| List of Reports Available for 2-Methoxy-5-[[[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]benzoic acid methyl ester |